Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are emerging problems in several countries. These infections require long and expensive treatment regimens. Recently, 2 new drugs, bedaquiline and delamanid, have been approved in several countries for use in adults with severe, difficult-to-treat MDR-TB, and it has been suggested that they could also be administered to children with MDR-TB and limited treatment options. However, no study has been completed on their efficacy.
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis : a case report and review of the literature / S. Esposito, S. Bosis, M. Tadolini, S. Bianchini, G.B. Migliori, N. Principi. - In: MEDICINE. - ISSN 0025-7974. - 95:46(2016 Nov), pp. e5347.1-e5347.4.
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis : a case report and review of the literature
S. EspositoPrimo
;S. BosisSecondo
;S. Bianchini;N. PrincipiUltimo
2016
Abstract
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are emerging problems in several countries. These infections require long and expensive treatment regimens. Recently, 2 new drugs, bedaquiline and delamanid, have been approved in several countries for use in adults with severe, difficult-to-treat MDR-TB, and it has been suggested that they could also be administered to children with MDR-TB and limited treatment options. However, no study has been completed on their efficacy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Esposito Bosis Efficacy safety tolerability of delamanid.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
176.64 kB
Formato
Adobe PDF
|
176.64 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
